Kisho

Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy

myasthenia gravis with thymus hyperplasia (Myas1) - Clinical Profile, Treatments & Trials | Kisho | Kisho

Rare Disease

myasthenia gravis with thymus hyperplasia

MONDO:0011768

Also known as:Myas1

Overview

Treatments1 FDA approved

ResearchLimited published research (7 articles)

Treatment

Compiled from FDA-approved drug records, orphan drug designations, and FDA Adverse Event Reporting System (FAERS) safety data. GeneReviews management guidance is included where available.

1 FDA-approved treatment is available for myasthenia gravis with thymus hyperplasia, including PYRIDOSTIGMINE BROMIDE (PYRIDOSTIGMINE BROMIDE, approved 1965).

Approved Therapies

Brand Name	Generic Name	Mechanism	Approved	Market Status

Research Landscape

Sourced from ClinicalTrials.gov and PubMed. Publication types are classified using NLM-curated article metadata; research type breakdowns reflect the nature of published work for this disease.

No clinical trials have been registered for myasthenia gravis with thymus hyperplasia.

7 publications have been identified in PubMed for myasthenia gravis with thymus hyperplasia. Research spans Basic Science / Preclinical (43%), Review / Meta-Analysis (29%), and Case Report / Case Series (14%).

Recent Publications

Wang X (2026). [PMID: 41948617](https://pubmed.ncbi.nlm.nih.gov/41948617/). *Front Neurol*. [Basic Science / Preclinical]
Theorell J (2026). [PMID: 41307955](https://pubmed.ncbi.nlm.nih.gov/41307955/). *JCI insight*. [Review / Meta-Analysis]
Jing S (2025). [PMID: 40892711](https://pubmed.ncbi.nlm.nih.gov/40892711/). *Neuroepidemiology*. [Epidemiology / Natural History]
Nowlan K (2025). [PMID: 39657004](https://pubmed.ncbi.nlm.nih.gov/39657004/). *The Journal of infectious diseases*. [Basic Science / Preclinical]
Dragin N (2025). [PMID: 40675741](https://pubmed.ncbi.nlm.nih.gov/40675741/). *International review of neurobiology*. [Review / Meta-Analysis]

Data assembled from 4 of 12 sources · Last updated Sep 20, 2026, 11:13 AM UTC

MONDOHPOClinicalTrials.govFDAPubMedHGNCClinVarClinGenGeneReviewsOrphanetOMIMRUSP

Patient Support

Financial & Access Support (External Programs)

View all programs →

Myasthenia Gravis Medical Assistance

Medical AssistanceCurrently AcceptingOperated by National Organization for Rare Disorders

Visit official site

Program availability and eligibility requirements are set by each foundation. Contact them directly to learn more about your options.

Are you a patient organization for this condition?

Claim this page and your organization will be listed here for patients and families to find.

Be recognized as the official organization
Get notified of new trials, FDA decisions, and research
Appear in the disease page directory
Embed this content on your website — free

Medical References

External Resources

OMIM

Online Mendelian Inheritance in Man

OMIM:607085

Questions for Your Care Team

→What are the benefits and potential side effects of PYRIDOSTIGMINE BROMIDE for managing myasthenia gravis with thymus hyperplasia?
→Are there specialists or centers of excellence for this condition in my area?
→Is there a patient registry I should consider joining?

← Back to All Diseases

myasthenia gravis with thymus hyperplasia

Overview

Treatment

Approved Therapies

Research Landscape

Recent Publications

Patient Support

Financial & Access Support (External Programs)

Are you a patient organization for this condition?

Medical References

External Resources

OMIM

Related Diseases

Questions for Your Care Team

Questions for Your Care Team

Clinical Trials